z-logo
open-access-imgOpen Access
Turning Defense into Offense: Defensin Mimetics as Novel Antibiotics Targeting Lipid II
Author(s) -
Kristen M. Varney,
Alexandre M. J. J. Bonvin,
Marzena Pazgier,
Jakob J Malin,
Wenbo Yu,
Eugene N. Ateh,
Taiji Oashi,
Wuyuan Lu,
Jing Huang,
Marlies Diepeveen-de Buin,
Joseph Bryant,
Eefjan Breukink,
Alexander D. MacKerell,
Erik P. H. de Leeuw
Publication year - 2013
Publication title -
plos pathogens
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.719
H-Index - 206
eISSN - 1553-7374
pISSN - 1553-7366
DOI - 10.1371/journal.ppat.1003732
Subject(s) - lipid a , lipid ii , peptide , lipopeptide , in vivo , biochemistry , defensin , in silico , chemistry , lipid metabolism , in vitro , antibiotics , biology , biological activity , biosynthesis , lipopolysaccharide , bacteria , enzyme , immunology , gene , genetics , microbiology and biotechnology
We have previously reported on the functional interaction of Lipid II with human alpha-defensins, a class of antimicrobial peptides. Lipid II is an essential precursor for bacterial cell wall biosynthesis and an ideal and validated target for natural antibiotic compounds. Using a combination of structural, functional and in silico analyses, we present here the molecular basis for defensin-Lipid II binding. Based on the complex of Lipid II with Human Neutrophil peptide-1, we could identify and characterize chemically diverse low-molecular weight compounds that mimic the interactions between HNP-1 and Lipid II. Lead compound BAS00127538 was further characterized structurally and functionally; it specifically interacts with the N-acetyl muramic acid moiety and isoprenyl tail of Lipid II, targets cell wall synthesis and was protective in an in vivo model for sepsis. For the first time, we have identified and characterized low molecular weight synthetic compounds that target Lipid II with high specificity and affinity. Optimization of these compounds may allow for their development as novel, next generation therapeutic agents for the treatment of Gram-positive pathogenic infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom